
|
|
Find IGF1R Products
Interaction Network for IGF1R
IGF1R Details
|
|
Related Pathways
Huntington's Disease Signaling Synaptic Long Term Depression IGF-1 Signaling View All Pathways
|
|

|
| Synonyms: A330103N21RIK, CD221, D930020L01, hyft, IGF-IR, IGF1 RECEPTOR, IGF1R, Igf1r beta, Igf1r beta isoform, IGFIRC, Igfr, IGFR1, JTK13, LOC51049, MGC142170, MGC142172, MGC18216, NM1 |
IGF1R Signaling
Insulin (IN), insulin-like growth factor-1 (IGF-1) (Somatomedin C) and insulin-like growth factor-2 (IGF-2) (Somatomedin A) activate cell signaling pathways through tyrosine kinase holoreceptors (tetrameric α2β2-receptors) composed of two hemi-receptors (half-receptors, α,β-heterodimers) composed of linked alpha and beta proteins. Insulin, IGF-1 and IGF-2 bind to these holoreceptors with different specificities and affinities depending upon the combinations of specific half-receptors. Insulin receptors exist as two isoforms, IR-A and IR-B, derived from different mRNAs. IR-A is expressed predominantly in the central nervous system, hematopoietic cells, buffy coat leukocytes, Epstein-Barr virus-transformed lymphocytes, fetal tissues and various malignant cells. IR-B is expressed predominantly in adipose tissue, liver and muscle. Holo-receptors can be composed of combinations of two insulin half-receptors (IR), two IGF-1 half-receptors or as hybrids composed of IR and IGF-1 half-receptors. IGF-I hemi-receptors can hetero-dimerize with either the A or B isoform IR hemi-receptor leading to the formation of A-type and B-type insulin/IGF-I hybrid receptors. IR-A:IGF-IR and the IR-B:IGF-IR hybrids have different binding affinities for insulin, IGF-I and IGF-II. The IGF-1R hemi-receptor typically dominates the downstream response to ligand binding to insulin hybrid receptors.
IGF-1 binds to IGF-1 homo- or hybrid holo-receptors and induces auto-phosphorylations within the cytoplasmic domain of the receptor followed by the binding of various adapter molecules that contribute to the specificity of down-stream signaling. IGF-1 stimulates the growth and survival of cells primarily through the activation of the PI3K/PDK1/Akt(PKB)/mTOR and the (SOS), RasGTPase/Raf-1/Mek/Erk signaling pathways which are linked to the receptor via adaptor molecules such as members of the insulin receptor substrate (IRS) family (IRS-1, IRS-2, IRS-3, IRS-4) and or Src homology 2 domain containing transforming protein (SHC). The IRS adaptors link to an array of downstream adaptors, such as Grb-2, Nck, Crk-II and CrkL that activate or modulate signaling pathways. IGF-1 is reported to promote cell spreading and contact with extracellular matrix through RACK-1, an IGF-1 receptor-interaction protein that also interacts with integrins and activated protein kinase C.
|
|
References:
- Chen, H. et. al. (1998) Identification of structural characteristics that contribute to a difference in antiapoptotic function between human insulin and insulin-like growth factor 1 receptors. Cell Growth Differ. 9, 939-947.
- Frasca, F. et. al. (2003) Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis. 17, 73-89.
- Hermanto, U. et. al. (2002) RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol Cell Biol. 22, 2345-2365.
- Kooijman R. et. al. (1995) Insulin-like growth factor induces phosphorylation of immunoreactive insulin receptor substrate and its association with phosphatidylinositol-3 kinase in human thymocytes. J Exp Med. 182, 593-597.
- Pandini, G. et. al. (2003) Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform A. J Biol Chem. 278, 42178-42189.
- Pandini, G. et. al. (2002) Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem. 277, 39684-39695.
- Valentinis, B. and Baserga, R. (2001) IGF-I receptor signalling in transformation and differentiation. Mol Pathol. 54, 133-137.
|
| Back to top |
Content for this page is provided by Dennis R. Conrad, Ph.D., a Life Science industry consultant with over 25 years of experience in the formulation and optimization of cell culture media. Dr. Conrad's email address is biomediaexpert@earthlink.net
|